|
US3691016A
(en)
|
1970-04-17 |
1972-09-12 |
Monsanto Co |
Process for the preparation of insoluble enzymes
|
|
CA1023287A
(en)
|
1972-12-08 |
1977-12-27 |
Boehringer Mannheim G.M.B.H. |
Process for the preparation of carrier-bound proteins
|
|
US4351337A
(en)
|
1973-05-17 |
1982-09-28 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery device, and process for preparing and using the same
|
|
US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
|
US4195128A
(en)
|
1976-05-03 |
1980-03-25 |
Bayer Aktiengesellschaft |
Polymeric carrier bound ligands
|
|
US4083368A
(en)
|
1976-09-01 |
1978-04-11 |
Freezer Winthrop J |
Inhaler
|
|
US4330440A
(en)
|
1977-02-08 |
1982-05-18 |
Development Finance Corporation Of New Zealand |
Activated matrix and method of activation
|
|
CA1093991A
(en)
|
1977-02-17 |
1981-01-20 |
Hideo Hirohara |
Enzyme immobilization with pullulan gel
|
|
US4229537A
(en)
|
1978-02-09 |
1980-10-21 |
New York University |
Preparation of trichloro-s-triazine activated supports for coupling ligands
|
|
US5002936A
(en)
|
1985-04-12 |
1991-03-26 |
Seymour Lieberman |
Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4925673A
(en)
|
1986-08-18 |
1990-05-15 |
Clinical Technologies Associates, Inc. |
Delivery systems for pharmacological agents encapsulated with proteinoids
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
DE3785186T2
(de)
|
1986-09-02 |
1993-07-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
|
AU607172B2
(en)
|
1986-12-22 |
1991-02-28 |
Cygnus, Inc. |
Diffusion matrix for transdermal drug administration
|
|
US4906169A
(en)
|
1986-12-29 |
1990-03-06 |
Rutgers, The State University Of New Jersey |
Transdermal estrogen/progestin dosage unit, system and process
|
|
US5023084A
(en)
|
1986-12-29 |
1991-06-11 |
Rutgers, The State University Of New Jersey |
Transdermal estrogen/progestin dosage unit, system and process
|
|
US4849224A
(en)
|
1987-11-12 |
1989-07-18 |
Theratech Inc. |
Device for administering an active agent to the skin or mucosa
|
|
US4983395A
(en)
|
1987-11-12 |
1991-01-08 |
Theratech Inc. |
Device for administering an active agent to the skin or mucosa
|
|
US4847325A
(en)
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
|
DE68925893T2
(de)
|
1988-07-23 |
1996-08-08 |
Delta Biotechnology Ltd |
Sekretorische leader-sequenzen
|
|
US4925677A
(en)
|
1988-08-31 |
1990-05-15 |
Theratech, Inc. |
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
|
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5171264A
(en)
|
1990-02-28 |
1992-12-15 |
Massachusetts Institute Of Technology |
Immobilized polyethylene oxide star molecules for bioapplications
|
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
|
JP3051145B2
(ja)
|
1990-08-28 |
2000-06-12 |
住友製薬株式会社 |
新規なポリエチレングリコール誘導体修飾ペプチド
|
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
|
ES2199935T3
(es)
|
1991-03-15 |
2004-03-01 |
Amgen Inc. |
Pegilacion de polipeptidos.
|
|
JP3507486B2
(ja)
|
1991-03-15 |
2004-03-15 |
アムジエン・インコーポレーテツド |
顆粒球コロニー刺激因子の肺内投与
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5792451A
(en)
|
1994-03-02 |
1998-08-11 |
Emisphere Technologies, Inc. |
Oral drug delivery compositions and methods
|
|
JPH0640945A
(ja)
|
1992-07-23 |
1994-02-15 |
Kureha Chem Ind Co Ltd |
Ｆｃフラグメント結合抗腫瘍剤
|
|
WO1994008599A1
(en)
|
1992-10-14 |
1994-04-28 |
The Regents Of The University Of Colorado |
Ion-pairing of drugs for improved efficacy and delivery
|
|
US5346701A
(en)
|
1993-02-22 |
1994-09-13 |
Theratech, Inc. |
Transmucosal delivery of macromolecular drugs
|
|
US5432155A
(en)
|
1993-06-29 |
1995-07-11 |
The Salk Institute For Biological Studies |
Conotoxins I
|
|
US5514774A
(en)
|
1993-06-29 |
1996-05-07 |
University Of Utah Research Foundation |
Conotoxin peptides
|
|
US5460820B1
(en)
|
1993-08-03 |
1999-08-03 |
Theratech Inc |
Method for providing testosterone and optionally estrogen replacement therapy to women
|
|
US6342225B1
(en)
|
1993-08-13 |
2002-01-29 |
Deutshces Wollforschungsinstitut |
Pharmaceutical active conjugates
|
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US5919455A
(en)
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US5446090A
(en)
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
|
AU1843295A
(en)
|
1994-02-23 |
1995-09-11 |
Chiron Corporation |
Method and compositions for increasing the serum half-life of pharmacologically active agents
|
|
FR2717688B1
(fr)
|
1994-03-28 |
1996-07-05 |
Lhd Lab Hygiene Dietetique |
Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
CN1170360A
(zh)
|
1994-12-21 |
1998-01-14 |
瑟垃技术有限公司 |
具有粘性贴面和剥离密封圆片的经皮输送系统
|
|
DE69530325T2
(de)
|
1994-12-22 |
2004-02-19 |
Astrazeneca Ab |
Aerosol-arzneiformulierungen
|
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5776896A
(en)
|
1996-01-03 |
1998-07-07 |
Zeneca Limited |
Analgesic peptides from venom of grammostola spatulata and use thereof
|
|
US5756663A
(en)
|
1996-01-03 |
1998-05-26 |
Zeneca Limited |
Antiarrhythmic peptide from venom of spider Grammostola spatulata
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US5783208A
(en)
|
1996-07-19 |
1998-07-21 |
Theratech, Inc. |
Transdermal drug delivery matrix for coadministering estradiol and another steroid
|
|
US6077680A
(en)
|
1996-11-27 |
2000-06-20 |
The University Of Florida |
ShK toxin compositions and methods of use
|
|
DE69734451T2
(de)
|
1996-12-26 |
2006-07-13 |
Suntory Limited |
Skorpion-spezifische neuropeptide
|
|
WO2000055371A1
(en)
|
1999-03-18 |
2000-09-21 |
Human Genome Sciences, Inc. |
27 human secreted proteins
|
|
US6548644B1
(en)
|
1997-03-10 |
2003-04-15 |
Immunex Corporation |
Site protected protein modification
|
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
|
JP3530004B2
(ja)
|
1998-02-06 |
2004-05-24 |
株式会社日立ユニシアオートモティブ |
吸入式投薬器
|
|
US6022952A
(en)
|
1998-04-01 |
2000-02-08 |
University Of Alberta |
Compositions and methods for protein secretion
|
|
US6451986B1
(en)
|
1998-06-22 |
2002-09-17 |
Immunex Corporation |
Site specific protein modification
|
|
AUPP589598A0
(en)
|
1998-09-14 |
1998-10-08 |
University Of Queensland, The |
Novel peptides
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
EP1132479B1
(en)
|
1998-11-20 |
2009-04-22 |
Fuso Pharmaceutical Industries Ltd. |
Protein expression vector and utilization thereof
|
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
|
KR100491815B1
(ko)
|
1998-12-23 |
2005-05-27 |
암젠 인코포레이티드 |
단백질의 서방성 수송을 위한 폴리올/오일 현탁액을 포함하는 제약학적 조성물 및 그것의 제조방법
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
WO2001038564A2
(en)
|
1999-11-26 |
2001-05-31 |
Mcgill University |
Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
|
|
CA2393616A1
(en)
|
2000-01-31 |
2001-08-02 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
WO2001062827A2
(en)
|
2000-02-22 |
2001-08-30 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
|
SE0000935D0
(sv)
|
2000-03-21 |
2000-03-21 |
Astrazeneca Ab |
An inhalation device
|
|
US7125847B1
(en)
|
2000-04-07 |
2006-10-24 |
The Research Foundation Of State University Of New York At Buffalo |
Mechanically activated channel blocker
|
|
CN1133461C
(zh)
|
2000-04-11 |
2004-01-07 |
厦门北大之路生物工程有限公司 |
虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用
|
|
CA2405550A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1280895B1
(en)
|
2000-05-10 |
2005-08-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Polypeptide inhibiting a proton-gated na+ channel
|
|
EP1177806A1
(en)
|
2000-08-04 |
2002-02-06 |
The Technology Partnership Public Limited Company |
Dry powder inhaler
|
|
GB0021617D0
(en)
|
2000-09-02 |
2000-10-18 |
Imp College Innovations Ltd |
Diagnosis and treatment of cancer
|
|
JP5013152B2
(ja)
|
2001-02-28 |
2012-08-29 |
株式会社ビーエムジー |
蛋白質複合体形成剤
|
|
CA2440582A1
(en)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Serum albumin binding moieties
|
|
US20050054051A1
(en)
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
CA2443968A1
(en)
|
2001-04-12 |
2002-10-24 |
Imperial College Innovations Limited |
Diagnosis and treatment of cancer: i
|
|
GB0120238D0
(en)
|
2001-08-20 |
2001-10-10 |
Univ College Of London |
Sodium channel regulators and modulators
|
|
US6887487B2
(en)
|
2001-10-19 |
2005-05-03 |
Idexx Laboratories, Inc. |
Injectable compositions for the controlled delivery of pharmacologically active compound
|
|
US6900317B2
(en)
|
2002-02-19 |
2005-05-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
|
|
US7125676B2
(en)
|
2002-02-25 |
2006-10-24 |
Vanderbilt University |
Expression system for human brain-specific voltage-gated sodium channel, type 1
|
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
|
ATE469135T1
(de)
|
2002-05-30 |
2010-06-15 |
Scripps Research Inst |
Kupferkatalysierte ligierung von aziden und acetylenen
|
|
GB0219512D0
(en)
|
2002-08-21 |
2002-10-02 |
Norton Healthcare Ltd |
Inhalation compositions with high drug ratios
|
|
ATE447025T1
(de)
|
2003-03-26 |
2009-11-15 |
Pharmadesign Inc |
Ionenkanalaktivität hemmende niedrigmolekulare peptide
|
|
ES2298785T3
(es)
|
2003-06-12 |
2008-05-16 |
Eli Lilly And Company |
Proteinas de fusion.
|
|
AR045445A1
(es)
|
2003-08-05 |
2005-10-26 |
Vertex Pharma |
Compuestos ihinibidores de canales ionicos regulados por voltaje
|
|
US7615563B2
(en)
|
2003-08-08 |
2009-11-10 |
Gonzalez Iii Jesus E |
Compositions useful as inhibitors of voltage-gated sodium channels
|
|
TW200524888A
(en)
|
2003-08-08 |
2005-08-01 |
Vertex Pharma |
Compositions useful as inhibitors of voltage-gated ion channels
|
|
US7125908B2
(en)
|
2003-08-29 |
2006-10-24 |
Allergan, Inc. |
Treating pain using selective antagonists of persistent sodium current
|
|
US7060723B2
(en)
|
2003-08-29 |
2006-06-13 |
Allergan, Inc. |
Treating neurological disorders using selective antagonists of persistent sodium current
|
|
AU2005207002B2
(en)
|
2004-01-21 |
2011-03-17 |
University Of Utah Research Foundation |
Mutant sodium channel Nav1.7 and methods related thereto
|
|
WO2005118614A1
(en)
|
2004-04-08 |
2005-12-15 |
Avigen, Inc. |
Methods and compositions for treating neuropathic pain
|
|
US7323169B2
(en)
|
2004-04-23 |
2008-01-29 |
Amgen Inc. |
Sustained release formulations
|
|
CN1973404B
(zh)
|
2004-06-23 |
2011-06-08 |
胡贝尔和茹纳股份公司 |
宽带贴片天线
|
|
GB0414272D0
(en)
|
2004-06-25 |
2004-07-28 |
Cellpep Sa |
OsK1 derivatives
|
|
US7259145B2
(en)
|
2004-07-07 |
2007-08-21 |
The Research Foundation Of State University Of New York |
Mechanically activated channel blocker
|
|
WO2006036834A2
(en)
|
2004-09-24 |
2006-04-06 |
Amgen Inc. |
MODIFIED Fc MOLECULES
|
|
EP1796709A4
(en)
|
2004-10-07 |
2009-10-28 |
Univ California |
ANALOGUES OF TOXIN SHK AND USES IN SELECTIVE INHIBITION OF KV1.3 POTASSIUM CHANNELS
|
|
JP2008519034A
(ja)
|
2004-11-03 |
2008-06-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
イオンチャネル調節剤としてのピリミジン誘導体および使用方法
|
|
US20060199812A1
(en)
|
2005-01-24 |
2006-09-07 |
Amgen Inc. |
Method of conjugating aminothiol containing molecules to vehicles
|
|
US7531523B2
(en)
|
2005-02-17 |
2009-05-12 |
Vertex Pharmaceuticals Incorporated |
Sodium channel protein type III alpha-subunit splice variant
|
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
GB0517487D0
(en)
|
2005-08-26 |
2005-10-05 |
Isis Innovation |
Antibodies
|
|
US7972813B2
(en)
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
|
JP2009514545A
(ja)
|
2005-11-08 |
2009-04-09 |
アテリス ラボラトリーズ |
μ−コノトキシンぺプチドおよびμ−コノトキシンぺプチドの局所麻酔薬としての使用
|
|
WO2007109324A2
(en)
|
2006-03-21 |
2007-09-27 |
Xenon Pharmaceuticals, Inc. |
Potent and selective nav 1.7 sodium channel blockers
|
|
EP2628749A3
(en)
|
2006-06-20 |
2013-12-04 |
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center |
Antimicrobial kinocidin compostions and methods of use
|
|
JP4742345B2
(ja)
*
|
2006-06-20 |
2011-08-10 |
独立行政法人産業技術総合研究所 |
カルシウムチャネルを遮断するグラモストラ・スパチュラタ由来のポリペプチドおよびその遺伝子
|
|
WO2008088422A2
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
|
CN101480393A
(zh)
*
|
2008-01-07 |
2009-07-15 |
云南昊邦制药有限公司 |
草乌甲素作为制备治疗Nav1.7疼痛病症药物的应用
|
|
EP2249856B1
(en)
|
2008-01-30 |
2013-11-06 |
Baylor College Of Medicine |
Peptides that target dorsal root ganglion neurons
|
|
BRPI0924225A2
(pt)
|
2009-02-02 |
2016-10-11 |
Chromocell Corp |
linhagens de células que expressam nav e métodos de uso
|
|
WO2010104114A1
(ja)
*
|
2009-03-10 |
2010-09-16 |
独立行政法人産業技術総合研究所 |
ポリペプチドライブラリーを調製する方法
|
|
WO2010104115A1
(ja)
|
2009-03-10 |
2010-09-16 |
独立行政法人産業技術総合研究所 |
膜タンパク質を特異的に認識するポリペプチドの調製方法
|
|
CA2755133A1
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Selective and potent peptide inhibitors of kv1.3
|
|
JP5555891B2
(ja)
|
2009-09-15 |
2014-07-23 |
アロモネ プリクリニカル リミテッド |
クモ毒から単離した新規ペプチド及びその使用
|
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
|
US8871996B2
(en)
|
2010-06-09 |
2014-10-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing human voltage-gated sodium channels
|
|
US9279003B2
(en)
|
2010-07-07 |
2016-03-08 |
Purdue Pharma L.P. |
Analogs of sodium channel peptide toxin
|
|
EP2852397B1
(en)
|
2012-05-18 |
2022-02-16 |
Janssen Biotech, Inc. |
Huwentoxin-iv variants and methods of use
|